A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy

Mario Del Rosso; Gabriella Fibbi; Anna Laurenzana; Francesca Margheri; Anastasia Chillà

doi:10.1016/j.jid.2021.05.004

A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy

J Invest Dermatol. 2021 Nov;141(11):2566-2568. doi: 10.1016/j.jid.2021.05.004.

Authors

Mario Del Rosso¹, Gabriella Fibbi², Anna Laurenzana², Francesca Margheri², Anastasia Chillà²

Affiliations

¹ Department of Experimental and Clinical Biomedical Sciences, School of Human Health Sciences, University of Florence, Florence, Italy. Electronic address: [email protected].
² Department of Experimental and Clinical Biomedical Sciences, School of Human Health Sciences, University of Florence, Florence, Italy.

PMID: 34688409
DOI: 10.1016/j.jid.2021.05.004

Abstract

In their new article in the Journal of Investigative Dermatology, Tseng et al. (2021) confirm that the sensitivity of melanoma cells to anti‒PD-L1 checkpoint inhibitor therapy is correlated with high PD-L1 surface expression. By blocking PD-L1 membrane clearing, controlled by LRP1 and PAI-1, the expression of high-cell-surface levels of PD-L1 was maintained.

Publication types

Comment

MeSH terms

Humans
Immunologic Factors
Immunotherapy
Melanoma* / drug therapy
Plasminogen Activator Inhibitor 1*

Substances

Immunologic Factors
Plasminogen Activator Inhibitor 1